Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature

References

1. CLSI 2002 Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts , approved standard, 2nd edn.M27–A2 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
2. Lee M. K., Williams L. E., Warnock D. W., Arthington-Skaggs B. A. 2004; Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 53:217–224 [CrossRef]
   [Google Scholar]
3. Marr K. A., Rustad T. R., Rex J. H., White T. C. 1999; The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 43:1383–1386
   [Google Scholar]
4. Pfaller M. A., Diekema D. J. 2004; Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida . Clin Microbiol Infect 10 (Suppl. 1):11–23 [CrossRef]
   [Google Scholar]
5. Revankar S. G., Kirkpatrick W. R., McAtee R. K., Fothergill A. W., Redding S. W., Rinaldi M. G., Patterson T. F. 1998; Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards Method. J Clin Microbiol 36:153–156
   [Google Scholar]
6. Rex J. H., Nelson P. W., Paetznick V. L., Lozano-Chiu M., Espinel-Ingroff A., Anaissie E. J. 1998; Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42:129–134
   [Google Scholar]
7. Sanglard D., Ischer F., Marchetti O., Entenza J., Bille J. 2003; Calcineurin A of Candida albicans : involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48:959–976 [CrossRef]
   [Google Scholar]